Parameter
| Biomarker | KMT2D | Full name | Lysine Methyltransferase 2D | Molecular Type | Nucleic acid (gene) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | TKI resistance prediction, therapeutic targets. |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Cell line/patient sample (siRNA-mediated knockdown, gene expression analysis) | ||
| Pathobiological Mechanisms | Mutation-induced imatinib resistance can be reduced by knockdown, and the expression can be restored to reverse the resistance. | ||||
| Clinical Availability Status | Research validation: Associated with upregulated CCNE2 expression. | ||||
| Notes and Dynamics | Histone modification enzyme-related markers provide novel strategies for overcoming drug resistance. | ||||